Scientific Publications


TransportNPC: A Phase 3 Global Trial of Trappsol® Cyclo™ Administered Intravenously to Patients with Niemann-Pick Disease Type C1 (NPC1)

          Authors: Joseph Mejia, MD / Lise Kjems, PhD, MD / Rebecca Fine / Caroline Hastings, MD





Top Line Results of Phase I Intravenous Trial for NPC

    • NNPDF Presentation
    • Caroline Hasting, MD
    • Jul 9, 2020

Trappsol® Cyclo™ is not currently approved for any indication.

Third-party websites are provided for convenience only. Cyclo Therapeutics, Inc. does not approve of, or endorse any of the content. Cyclo Therapeutics, Inc. does not maintain, control or monitor the content of third-party websites in any way.